When was Recursion Pharmaceuticals founded?

Recursion Pharmaceuticals was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is Recursion Pharmaceuticals located?

Recursion Pharmaceuticals is headquartered in New York, United States. It is registered at Salt Lake City, Utah.

How many employees does Recursion Pharmaceuticals have?

As of Mar 31, 2026, the latest employee count at Recursion Pharmaceuticals is 755.

Is Recursion Pharmaceuticals a funded company?

Recursion Pharmaceuticals is a funded company, having raised a total of $452M across 19 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 01, 2014.

When was the latest funding round of Recursion Pharmaceuticals?

Recursion Pharmaceuticals' latest funding was a $***** Post IPO round on Jul 12, 2023, with participation from 1 investor.

What is the annual revenue of Recursion Pharmaceuticals?

Annual revenue of Recursion Pharmaceuticals is between $50M and $100M as on Dec 31, 2025

Where does Recursion Pharmaceuticals rank among its competitors?

Recursion Pharmaceuticals ranks 2nd amongst 209 active competitors, of which 71 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Isomorphic Labs, which secured $2.1B in May, 2026.

Who are the top competitors of Recursion Pharmaceuticals?

Recursion Pharmaceuticals' top competitors include Schrodinger, Valo Health and XtalPi. Among them, Isomorphic Labs secured the most recent funding round in May, 2026.

Recursion Pharmaceuticals - 2026 Company Profile, Funding, Competitors & Financials

Company Details

AI-enabled drug discovery and development platform for novel therapeutics. It focuses on identifying new targets and designing optimized molecules. The platform utilizes biological and chemical datasets, machine learning models, and a supercomputer to accelerate the discovery of medicines. It aims to improve the speed and efficiency of drug development for conditions with high unmet needs, including cancers and rare diseases. The company also forms strategic partnerships to expand its impact on patients.

Website: recursion.com
Social
Email ID: *****@recursion.com
Phone Number: +1 **********
Registered Address: Salt Lake City, Utah

Key Metrics

Founded Year

2013

Location

New York, United States

Stage

Public

Total Funding

$452M in 19 rounds

Latest Funding Round

Post IPO, Jul 12, 2023, $*****

Investors

Felicis Ventures & 48 more

Ranked

2^nd among 209 active competitors

Annual Revenue

$50M - $100M as on Dec 31, 2025

Employee Count

755 as on Mar 31, 2026

Investment & Acquisitions

Exscientia & 3 more

Similar Companies

OpenEvidence & 2534 more

Exit Details

Public

View Recursion Pharmaceuticals' full profile

Recursion Pharmaceuticals is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Recursion Pharmaceuticals, Inc. CIN: 6727635 , United States, Active	Feb 08, 2023	-	-	-
RECURSION PHARMACEUTICALS, INC. CIN: 1601830 , United States, Active	Apr 01, 2014	$50M - $100M (As on Dec 31, 2025)	400 (As on Dec 31, 2021)	-
RECURSION PHARMACEUTICALS LLC CIN: 464099738 , United States, Active	Dec 31, 1999	-	453 (As on Dec 31, 2024)	-
Recursion Pharmaceuticals, LLC CIN: 1601830 , United States, Active		$1 - $1M (As on Dec 04, 2015)	-	-

Recursion Pharmaceuticals got listed on Apr 16, 2021.

Click here to take a look at Recursion Pharmaceuticals's IPO in detail

Recursion Pharmaceuticals has raised a total funding of $452M over 19 rounds. Its first funding round was on Jan 01, 2014. Its latest funding round was a Post IPO round on Jul 12, 2023 for $*****. 1 investor participated in its latest round. Recursion Pharmaceuticals has 49 institutional investors.

Here is the list of recent funding rounds of Recursion Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 12, 2023	3237275	Post IPO	5402123	1078609	3790174	8224329
Oct 25, 2022	3468637	Post IPO	2127671	1278858	5944006	Kinnevik & 4 more
Sep 09, 2020	2834134	Series D	6156939	7162296	Leaps by Bayer & 14 more	Laurion Capital

Access funding benchmarks and valuations. Sign up today!

View details of Recursion Pharmaceuticals's funding rounds and investors

Recursion Pharmaceuticals' employee count trend

Recursion Pharmaceuticals has 755 employees as of Mar 26. Here is Recursion Pharmaceuticals's employee count trend over the years:

Employee count trend for Recursion Pharmaceuticals

Uncover Recursion Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Recursion Pharmaceuticals include Schrodinger, Valo Health and XtalPi. Here is the list of Top 10 competitors of Recursion Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Schrodinger 1990, New York City (United States), Acquired	Provider of a web-based simulation and modelling tool	$162M	Gates, WuXi AppTec & 16 others	74/100
2nd	Recursion Pharmaceuticals 2013, New York (United States), Public	AI-enabled drug discovery and development platform for novel therapeutics	$452M	HTIF, AME Cloud Ventures & 47 others	72/100
3rd	Valo Health 2019, Boston (United States), Series B	AI-powered platform for drug discovery and development	$450M	PSP Investments, Koch Disruptive Technologies ... & 7 others	67/100
4th	XtalPi 2014, Cambridge (United States), Public	AI-based drug research and development company	$785M	Orbimed, SoftBank Vision Fund & 25 others	67/100
5th	Isomorphic Labs 2021, London (United Kingdom), Series B	Digital platform focused on revolutionizing drug discovery using AI	$2.7B	Thrive Capital, CapitalG & 6 others	64/100
6th	Xaira 2023, San Francisco (United States), Series D	AI-enabled platform for drug discovery and development	$1B	Arch Venture Partners, Foresite Labs & 11 others	63/100
7th	In Silico 2014, Cambridge (United States), Public	AI-enabled bioinformatics platform for drug discovery and biomarker development	$510M	Qiming Venture Partners, Prosperity7 Ventures ... & 36 others	62/100
8th	Tandem AI 2021, New York (United States), Series A	AI-based drug discovery tool for researchers	$82M	Orbimed, Chengwei Capital & 4 others	62/100
9th	Causaly 2018, London (United Kingdom), Series B	Provider of an AI platform for life sciences and biomedical research	$93M	EBRD, Iconiq Capital & 14 others	62/100
10th	Aqemia 2019, Paris (France), Series A	Provider of an AI and quantum physics to discover therapeutic molecules	$101M	Cathay Innovation, Elaia & 4 others	62/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Recursion Pharmaceuticals's competitors? Click here to see the top ones

Recursion Pharmaceuticals has not made any investments yet. Recursion Pharmaceuticals has made 4 acquisitions.

Here is the list of latest three $acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Aug 08, 2024	Acquisition	Exscientia	2012	Oxford (United Kingdom)
May 08, 2023	Acquisition	Cyclica	2013	Toronto (Canada)
May 08, 2023	Acquisition	Valence Labs	2017	Montreal (Canada)

Want to know more about where corporates are investing? Sign up today!

See all acquisitions by Recursion Pharmaceuticals

Here is the latest report on Recursion Pharmaceuticals's sector:

Free

Life Sciences Tech - Sector Report

Edition: July, 2026 (83 Pages)

View all reports related to Recursion Pharmaceuticals

Media has covered Recursion Pharmaceuticals for a total of 23 events in the last 1 year, 9 of them have been about company updates and 4 about people movement.